Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: Influence of a sustained HCV response

Journal of Viral Hepatitis

Volumn 19, Issue 6, 2012, Pages 431-435

  Bani Sadr, F ^a   Krastinova, E ^a   Fromentin, D ^a   Piroth, L ^b   Rosenthal, E ^c   Quertainmont, Y ^d   Perronne, C ^e   Cacoub, P ^f   Pol, S ^g   Carrat, F ^a  

^a INSERM   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF NICE   (France)

^d BICÊTRE HOSPITAL   (France)

^e RAYMOND POINCARÉ HOSPITAL   (France)

^f Sorbonne Université   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

antiretroviral therapy; AST ALT elevation; HCV sustained viral response; HIV HCV coinfection; severe cytolysis; stavudine; transaminitis

Indexed keywords

ABACAVIR; ALPHA2B INTERFERON; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRANSAMINASEMIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; VIRUS LOAD;

ADULT; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTATE AMINOTRANSFERASES; COHORT STUDIES; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERONS; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN;

EID: 84861094480     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01570.x     Document Type: Article

References (25)

1. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073-1089. (Pubitemid 46763278)
2. Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 40: 588-593. (Pubitemid 40270230)
3. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313. (Pubitemid 34465173)
4. Bani-Sadr F, Lapidus N, Bedossa P, et al. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis 2008; 46: 768-774. (Pubitemid 351321564)
5. Bani-Sadr F, Carrat F, Rosenthal E, et al. Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment. Clin Infect Dis 2005; 41: 1806-1809. (Pubitemid 41759869)
6. Lissen E, Clumeck N, Sola R, et al. Histological response to pegIFNalpha-2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS 2006; 20: 2175-2181. (Pubitemid 44684708)
7. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-2848. (Pubitemid 39628231)
8. de Mendoza C, Martin-Carbonero L, Barreiro P, et al. Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy. AIDS 2007; 21: 583-588.
9. Uberti-Foppa C, De Bona A, Morsica G, et al. Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 33: 146-152. (Pubitemid 36793147)
10. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD,. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002; 35: 182-189. (Pubitemid 34032559)
11. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD,. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18: 2277-2284. (Pubitemid 39620220)
12. Martinez E, Blanco JL, Arnaiz JA, et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 2001; 15: 1261-1268. (Pubitemid 32592358)
13. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V,. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 426-431. (Pubitemid 32801070)
14. Birkus G, Hitchcock MJ, Cihlar T,. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46: 716-723. (Pubitemid 34157656)
15. Kovari H, Ledergerber B, Battegay M, et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. Clin Infect Dis 2010; 50: 502-511.
16. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43: 365-372. (Pubitemid 44078910)
17. Zeremski M, Talal AH,. Dideoxynucleoside analogues should be used cautiously in patients with hepatic steatosis. Clin Infect Dis 2006; 43: 373-376. (Pubitemid 44078911)
18. Blanco F, Barreiro P, Ryan P, et al. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011; 18:(1): 11-16.
19. Rodriguez-Torres M, Govindarajan S, Sola R, et al. Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study. J Hepatol 2008; 48: 756-764.
20. Merchante N, Perez-Camacho I, Mira JA, et al. Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine. Antivir Ther 2010; 15: 753-763.
21. Vispo E, Moreno A, Maida I, et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS 2010; 24: 1171-1176.
22. Rivero A, Mira JA, Pineda JA,. Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007; 59: 342-346. (Pubitemid 47073440)
23. Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55. (Pubitemid 41772515)
24. Bani-Sadr F, Bedossa P, Rosenthal E, et al. Does early antiretroviral treatment prevent liver fibrosis in HIV/HCV-coinfected patients? J Acquir Immune Defic Syndr 2009; 50: 234-236.
25. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9: 82-88. (Pubitemid 351228130)